TiumBio Applies for Phase 2a Clinical Trial Plan of Endometriosis Treatment in Europe

[Asia Economy Reporter Junhyung Lee] Tium Bio announced on the 17th that it will apply for the Phase 2a clinical trial plan of the endometriosis treatment TU2670 in European countries such as Italy and Poland.

Through this clinical trial, the safety of TU2670 will be confirmed in female patients experiencing pain due to moderate to severe endometriosis.

The company explained that, unlike existing treatments, this drug has no initial side effects and minimizes serious side effects such as bone loss through dose adjustment. It is orally administered, making it more convenient to take than existing treatments and can be discontinued at any time.

The company plans to conduct the clinical trial at 40 clinical trial institutions in five European countries, including Ukraine and Russia.

Previously, in October and November, Tium Bio received approval for the clinical trial from the Ministry of Health (MOH) of the Russian Federation and the Ministry of Health of Ukraine.